Locations:
Search IconSearch
January 16, 2018/Pulmonary

CNS Granulomata in Common Variable Immunodeficiency

A better understanding and a hope for better outcomes

18-RHE-1022-Hajj-Ali-Hero-Image-650x450pxl

By Rula Hajj-Ali, MD, Daniel Culver, DO, and James Fernandez, MD, PhD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Although common variable immunodeficiency (CVID) typically involves hypogammaglobulinemia and recurrent infections, between 8 and 22 percent of patients also develop granulomatous disease. We have very little data regarding the presence of granulomatous disease in the central nervous system (CNS), and in this case series, we’ve tried to pinpoint clinicopathologic features that may prompt further study.

Patient cohort & characteristics

CVID, the second most common primary immunodeficiency syndrome, is characterized by marked decreases in immunoglobulin concentration and frequently decreased B and T lymphocytes. We examined 19 patients with CVID and CNS manifestations — four Cleveland Clinic patients and 15 from a comprehensive search of the medical literature.

CNS manifestations included:

  • Seizures (31.6 percent)
  • Headaches (21 percent)
  • Vision loss (15.7 percent)
  • Decreased cognition (10.5 percent)
  • Focal weakness (5.2 percent)
  • Nystagmus (5.2 percent)
  • Ataxia (5.2 percent)
  • Coma (5.2 percent)
  • Polydipsia (5.2 percent)

The patients were mostly white and female and were also likely to have lung involvement. Recurrent infections were common, and several concurrent autoimmune diseases were documented. Interestingly, five patients had a family history of autoimmune diseases.

Of the 12 patients with brain pathologic findings, 50 percent had angiocentric granulomas. The mean age of CNS granulomatous disease diagnosis (21.5 years) was lower than that of CVID diagnosis (24 years). An earlier report showed that a diagnosis of granulomatous disease prior to the CVID diagnosis is common (41 percent) and that delayed diagnosis of CVID may worsen prognosis significantly.

Advertisement

Treatments and outcomes

The table below describes the variation in treatment offered to patients, as current guidelines are limited and based on case reports. Determining the optimal treatment regimen for granulomas in CVID is a path of inquiry ripe for clinical research.

A better understanding, a hope for better outcomes

While granulomatous diseases have been associated with CVID, this first-of-its-kind case series raises awareness of the association between granulomatous diseases in the central nervous system in association of CVID. These data add to the diagnostic landscape of CNS granulomatous disease and provide an overview of the varying treatments currently in use for these rare manifestations of an already rare disease.

Dr. Hajj-Ali is Associate Director of the Center for Vasculitis Care and Research in the Department of Rheumatic and Immunologic Diseases. Dr. Culver is Director of the Sarcoidosis and Interstitial Lung Disease Program in the Respiratory Institute. Dr. Fernandez is staff in the Department of Allergy and Clinical Immunology.

Feature image: Demonstrates two blood vessels in the meninges (movatstain) — one vessel is normal and the other is overrun by inflammatory cells; (B) a large area of geographic necrosis with nuclear debris; the adjacent are as reveal a predominantly chronic inflammatory cellular infiltrate; and (C) a non-necrotizing granuloma. Image and caption republished with permission from Elsevier.

Advertisement

Related Articles

Medical Ventilator
December 19, 2025/Pulmonary/Critical Care
Closing the Ventilator Training Gap with SEVA

The progressive training program aims to help clinicians improve patient care

Patient receiving shot in arm
November 26, 2025/Pulmonary/Asthma
Biologics for Asthma and COPD: What Providers Need to Know

New breakthroughs are shaping the future of COPD management and offering hope for challenging cases

Patient speaking with physician
November 11, 2025/Pulmonary/Podcast
Relieving the Chronic Cough Burden: From Expert Evaluation to Emerging Therapies (Podcast)

Exploring the impact of chronic cough from daily life to innovative medical solutions

Physician with ultrasound device
October 20, 2025/Pulmonary/Podcast
Building a POCUS Powerhouse: Point-of-Care Ultrasound Workflow, Training and Innovation in Pulmonary Critical Care (Podcast)

How Cleveland Clinic transformed a single ultrasound machine into a cutting-edge, hospital-wide POCUS program

Patient scan
Checkpoint Inhibitor Pneumonitis: A Rare But Potentially Serious Lung Toxicity

Collaborative patient care, advanced imaging techniques support safer immunotherapy management

Medical illustration of lungs
September 25, 2025/Pulmonary/News & Insight
Advancing Cystic Fibrosis Treatment with mRNA Therapies

Potential options for patients who do not qualify for modulator therapies

Coal miner in shaft
Coal Workers' Pneumoconiosis: Forgotten, But Not Gone

Rising rates in young miners illustrate the need for consistent prevention messaging from employers and clinicians

pharmacist talking with physician
July 15, 2025/Pulmonary/Research
Study Highlights Role of Pharmacist Recommendations in Antibiotic Stewardship

Clinicians generally follow pharmacist advice, but more can be done

Ad